Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis

Eur J Intern Med. 2021 Mar:85:130-132. doi: 10.1016/j.ejim.2020.11.021. Epub 2021 Jan 5.
No abstract available

Keywords: Alirocumab; Evolocumab; Lipid-lowering; PCSK9 inhibitor; Statin; Stroke.

Publication types

  • Letter
  • Meta-Analysis

MeSH terms

  • Anticholesteremic Agents*
  • Cardiovascular Diseases*
  • Humans
  • Proprotein Convertase 9
  • Stroke* / prevention & control
  • Subtilisins

Substances

  • Anticholesteremic Agents
  • Proprotein Convertase 9
  • Subtilisins